<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00834210</url>
  </required_header>
  <id_info>
    <org_study_id>MA-ACZ0802</org_study_id>
    <nct_id>NCT00834210</nct_id>
  </id_info>
  <brief_title>Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <brief_summary>
    <textblock>
      A 12-week evaluation of the safety and efficacy of dapsone gel 5% when used with tazarotene
      cream 0.1% compared with tazarotene cream 0.1% monotherapy in treating moderate to severe
      facial acne vulgaris
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Inflammatory Lesion Counts (Papules,Pustules, and Nodules) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in inflammatory lesion count (papules, pustules and nodules) at week 12. Papules and nodules are round, solid elevations of the skin with no visible fluid; papules are smaller (less than 5 or 10 millimeters in width and depth) and nodules are larger (greater than 5 or 10 millimeters in width and depth). Pustules are small elevations of the skin containing cloudy material. A negative number change from baseline indicates a reduction in lesion counts (improvement).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Investigator Global Assessment at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in the Investigator Global Assessment (IGA) at week 12. The IGA is a 5-point scale used by the investigator to assess overall acne severity, where 0 equals clear skin (no evidence of acne) and 4 equals severe acne. A negative number change from baseline indicates a reduction in acne severity (improvement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Overall Disease Severity at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in overall disease severity at week 12. The overall disease severity was evaluated by the investigator using a 7-point scale to rate the overall acne severity (lesions, inflammation, facial redness and skin condition), where 0=no acne lesions and 6=most severe acne. A negative number change from baseline indicates a reduction in overall acne disease severity (improvement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Non-Inflammatory Lesion Counts (Open and Closed Comedones) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in non-inflammatory lesion counts(open/closed comedones) at week 12. Comedones are small bumps on the skin (lesions) caused by acne and found at the opening of a skin pore. Open comedones (also known as blackheads) have a microscopic opening to the skin surface, while closed comedones (also known as whiteheads or &quot;pimples&quot;) lack the opening to the skin. A negative number change from baseline indicates a reduction in lesion counts (improvement).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dapsone Gel 5% and Tazarotene Cream 0.1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tazarotene Cream 0.1%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapsone</intervention_name>
    <description>Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Aczone Gel 5%; Tazorac Cream 0.1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazarotene</intervention_name>
    <description>Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Tazorac Cream 0.1%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Facial acne vulgaris characterized by the following: 30-100 facial inflammatory
             lesions; and 25-100 facial non-inflammatory lesions; stable disease, non-rapidly
             regressing facial acne vulgaris; and, 3 or more nodules and/or cysts (diameter of 1cm
             or greater). Female subjects of childbearing potential must have a negative pregnancy
             test at baseline and practice reliable method of contraception throughout the study

        Exclusion Criteria:

          -  Non-compliance with washout period; history of clinically significant anemia or
             hemolysis; skin disease/disorder that might interfere with diagnosis or evaluation of
             acne vulgaris; allergy or sensitivity to any component of the test medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2009</study_first_submitted>
  <study_first_submitted_qc>January 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <results_first_submitted>September 22, 2011</results_first_submitted>
  <results_first_submitted_qc>September 22, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 31, 2011</results_first_posted>
  <last_update_submitted>September 22, 2011</last_update_submitted>
  <last_update_submitted_qc>September 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapsone</mesh_term>
    <mesh_term>Tazarotene</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dapsone Gel 5% and Tazarotene Cream 0.1%</title>
          <description>Dapsone Gel 5% and Tazarotene Cream 0.1%</description>
        </group>
        <group group_id="P2">
          <title>Tazarotene Cream 0.1%</title>
          <description>Tazarotene Cream 0.1%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dapsone Gel 5% and Tazarotene Cream 0.1%</title>
          <description>Dapsone Gel 5% and Tazarotene Cream 0.1%</description>
        </group>
        <group group_id="B2">
          <title>Tazarotene Cream 0.1%</title>
          <description>Tazarotene Cream 0.1%</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
            <count group_id="B2" value="85"/>
            <count group_id="B3" value="171"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.8" lower_limit="12.2" upper_limit="45.7"/>
                    <measurement group_id="B2" value="16.7" lower_limit="12.1" upper_limit="42.9"/>
                    <measurement group_id="B3" value="17.2" lower_limit="12.1" upper_limit="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Inflammatory Lesion Counts (Papules,Pustules, and Nodules) at Week 12</title>
        <description>Change from baseline in inflammatory lesion count (papules, pustules and nodules) at week 12. Papules and nodules are round, solid elevations of the skin with no visible fluid; papules are smaller (less than 5 or 10 millimeters in width and depth) and nodules are larger (greater than 5 or 10 millimeters in width and depth). Pustules are small elevations of the skin containing cloudy material. A negative number change from baseline indicates a reduction in lesion counts (improvement).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-treat (ITT), which included all patients who started the study (randomized).</population>
        <group_list>
          <group group_id="O1">
            <title>Dapsone Gel 5% and Tazarotene Cream 0.1%</title>
            <description>Dapsone Gel 5% and Tazarotene Cream 0.1%</description>
          </group>
          <group group_id="O2">
            <title>Tazarotene Cream 0.1%</title>
            <description>Tazarotene Cream 0.1%</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Inflammatory Lesion Counts (Papules,Pustules, and Nodules) at Week 12</title>
          <description>Change from baseline in inflammatory lesion count (papules, pustules and nodules) at week 12. Papules and nodules are round, solid elevations of the skin with no visible fluid; papules are smaller (less than 5 or 10 millimeters in width and depth) and nodules are larger (greater than 5 or 10 millimeters in width and depth). Pustules are small elevations of the skin containing cloudy material. A negative number change from baseline indicates a reduction in lesion counts (improvement).</description>
          <population>Intent-to-treat (ITT), which included all patients who started the study (randomized).</population>
          <units>Number of Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.94" spread="11.67"/>
                    <measurement group_id="O2" value="40.78" spread="12.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.77" spread="11.23"/>
                    <measurement group_id="O2" value="-24.82" spread="14.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Investigator Global Assessment at Week 12</title>
        <description>Change from baseline in the Investigator Global Assessment (IGA) at week 12. The IGA is a 5-point scale used by the investigator to assess overall acne severity, where 0 equals clear skin (no evidence of acne) and 4 equals severe acne. A negative number change from baseline indicates a reduction in acne severity (improvement).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-treat (ITT), which included all patients who started the study (randomized)</population>
        <group_list>
          <group group_id="O1">
            <title>Dapsone Gel 5% and Tazarotene Cream 0.1%</title>
            <description>Dapsone Gel 5% and Tazarotene Cream 0.1%</description>
          </group>
          <group group_id="O2">
            <title>Tazarotene Cream 0.1%</title>
            <description>Tazarotene Cream 0.1%</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Investigator Global Assessment at Week 12</title>
          <description>Change from baseline in the Investigator Global Assessment (IGA) at week 12. The IGA is a 5-point scale used by the investigator to assess overall acne severity, where 0 equals clear skin (no evidence of acne) and 4 equals severe acne. A negative number change from baseline indicates a reduction in acne severity (improvement).</description>
          <population>Intent-to-treat (ITT), which included all patients who started the study (randomized)</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" spread="0.37"/>
                    <measurement group_id="O2" value="3.04" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" spread="0.96"/>
                    <measurement group_id="O2" value="-0.96" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Overall Disease Severity at Week 12</title>
        <description>Change from baseline in overall disease severity at week 12. The overall disease severity was evaluated by the investigator using a 7-point scale to rate the overall acne severity (lesions, inflammation, facial redness and skin condition), where 0=no acne lesions and 6=most severe acne. A negative number change from baseline indicates a reduction in overall acne disease severity (improvement).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-treat (ITT), which included all patients who started the study (randomized).</population>
        <group_list>
          <group group_id="O1">
            <title>Dapsone Gel 5% and Tazarotene Cream 0.1%</title>
            <description>Dapsone Gel 5% and Tazarotene Cream 0.1%</description>
          </group>
          <group group_id="O2">
            <title>Tazarotene Cream 0.1%</title>
            <description>Tazarotene Cream 0.1%</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Overall Disease Severity at Week 12</title>
          <description>Change from baseline in overall disease severity at week 12. The overall disease severity was evaluated by the investigator using a 7-point scale to rate the overall acne severity (lesions, inflammation, facial redness and skin condition), where 0=no acne lesions and 6=most severe acne. A negative number change from baseline indicates a reduction in overall acne disease severity (improvement).</description>
          <population>Intent-to-treat (ITT), which included all patients who started the study (randomized).</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.03" spread="0.73"/>
                    <measurement group_id="O2" value="4.08" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.93" spread="1.11"/>
                    <measurement group_id="O2" value="-1.63" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Non-Inflammatory Lesion Counts (Open and Closed Comedones) at Week 12</title>
        <description>Change from baseline in non-inflammatory lesion counts(open/closed comedones) at week 12. Comedones are small bumps on the skin (lesions) caused by acne and found at the opening of a skin pore. Open comedones (also known as blackheads) have a microscopic opening to the skin surface, while closed comedones (also known as whiteheads or &quot;pimples&quot;) lack the opening to the skin. A negative number change from baseline indicates a reduction in lesion counts (improvement).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-treat (ITT), which included all patients who started the study (randomized).</population>
        <group_list>
          <group group_id="O1">
            <title>Dapsone Gel 5% and Tazarotene Cream 0.1%</title>
            <description>Dapsone Gel 5% and Tazarotene Cream 0.1%</description>
          </group>
          <group group_id="O2">
            <title>Tazarotene Cream 0.1%</title>
            <description>Tazarotene Cream 0.1%</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Non-Inflammatory Lesion Counts (Open and Closed Comedones) at Week 12</title>
          <description>Change from baseline in non-inflammatory lesion counts(open/closed comedones) at week 12. Comedones are small bumps on the skin (lesions) caused by acne and found at the opening of a skin pore. Open comedones (also known as blackheads) have a microscopic opening to the skin surface, while closed comedones (also known as whiteheads or &quot;pimples&quot;) lack the opening to the skin. A negative number change from baseline indicates a reduction in lesion counts (improvement).</description>
          <population>Intent-to-treat (ITT), which included all patients who started the study (randomized).</population>
          <units>Number of lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.42" spread="17.40"/>
                    <measurement group_id="O2" value="46.48" spread="16.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.73" spread="15.08"/>
                    <measurement group_id="O2" value="-21.74" spread="18.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dapsone Gel 5% and Tazarotene Cream 0.1%</title>
          <description>Dapsone Gel 5% and Tazarotene Cream 0.1%</description>
        </group>
        <group group_id="E2">
          <title>Tazarotene Cream 0.1%</title>
          <description>Tazarotene Cream 0.1%</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Medical Affairs</name_or_title>
      <organization>Allergan, Inc.</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

